Dr. Reddy’s today announced the commercial launch of 2-deoxy-D-glucose (2-DG).
Dr. Reddy’s will supply to major Government as well as private hospitals across India.
In the initial weeks, the Company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of India.
2-DG manufactured by Dr. Reddy’s has a purity of 99.5% and is being sold commercially under the brand name 2DGTM. The maximum retail price (MRP) of each sachet has been fixed at Rs. 990, with a subsidized rate offered to Government institutions. Enquiries for 2DGTM can be sent to 2DG[at]drreddys[dot]com.
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s. 2-DG is an oral drug.
It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. Emergency use approval for anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021